376 related articles for article (PubMed ID: 25929572)
1. Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy.
Kim YD; Park TE; Singh B; Maharjan S; Choi YJ; Choung PH; Arote RB; Cho CS
Nanomedicine (Lond); 2015; 10(7):1165-88. PubMed ID: 25929572
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?
Aghamiri S; Mehrjardi KF; Shabani S; Keshavarz-Fathi M; Kargar S; Rezaei N
Nanomedicine (Lond); 2019 Aug; 14(15):2083-2100. PubMed ID: 31368405
[TBL] [Abstract][Full Text] [Related]
3. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy.
De Backer L; Cerrada A; Pérez-Gil J; De Smedt SC; Raemdonck K
J Control Release; 2015 Dec; 220(Pt B):642-50. PubMed ID: 26363301
[TBL] [Abstract][Full Text] [Related]
4. Effect of siRNA pre-Exposure on Subsequent Response to siRNA Therapy.
Aliabadi HM; Mahdipoor P; Kucharsky C; Chan N; Uludağ H
Pharm Res; 2015 Dec; 32(12):3813-26. PubMed ID: 26129766
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in siRNA delivery.
Sarisozen C; Salzano G; Torchilin VP
Biomol Concepts; 2015 Dec; 6(5-6):321-41. PubMed ID: 26609865
[TBL] [Abstract][Full Text] [Related]
6. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems.
Babu A; Munshi A; Ramesh R
Drug Dev Ind Pharm; 2017 Sep; 43(9):1391-1401. PubMed ID: 28523942
[TBL] [Abstract][Full Text] [Related]
8. Atom Transfer Radical Polymerization of Multishelled Cationic Corona for the Systemic Delivery of siRNA.
Kim HS; Son YJ; Mao W; Leong KW; Yoo HS
Nano Lett; 2018 Jan; 18(1):314-325. PubMed ID: 29232130
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution and pharmacokinetics of Mad2 siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer models.
Nascimento AV; Gattacceca F; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
Nanomedicine (Lond); 2016 Apr; 11(7):767-81. PubMed ID: 26980454
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral delivery and therapeutic efficacy of nanoparticle-encapsulated anti-tumor siRNA following intrapulmonary administration for potential treatment of lung cancer.
Kanehira Y; Togami K; Ishizawa K; Sato S; Tada H; Chono S
Pharm Dev Technol; 2019 Nov; 24(9):1095-1103. PubMed ID: 31204552
[TBL] [Abstract][Full Text] [Related]
11. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
Hatakeyama H; Wu SY; Mangala LS; Lopez-Berestein G; Sood AK
Methods Mol Biol; 2016; 1402():189-197. PubMed ID: 26721492
[TBL] [Abstract][Full Text] [Related]
12. Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration.
Muralidharan R; Babu A; Amreddy N; Basalingappa K; Mehta M; Chen A; Zhao YD; Kompella UB; Munshi A; Ramesh R
J Nanobiotechnology; 2016 Jun; 14(1):47. PubMed ID: 27328938
[TBL] [Abstract][Full Text] [Related]
13. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.
Ku SH; Kim K; Choi K; Kim SH; Kwon IC
Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
Li SD; Huang L
Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
[TBL] [Abstract][Full Text] [Related]
15. Polymer-Coated Extracellular Vesicles for Selective Codelivery of Chemotherapeutics and siRNA to Cancer Cells.
Jhan YY; Palou Zuniga G; Singh KA; Gaharwar AK; Alge DL; Bishop CJ
ACS Appl Bio Mater; 2021 Feb; 4(2):1294-1306. PubMed ID: 35014481
[TBL] [Abstract][Full Text] [Related]
16. Ultra-pH-Responsive and Tumor-Penetrating Nanoplatform for Targeted siRNA Delivery with Robust Anti-Cancer Efficacy.
Xu X; Wu J; Liu Y; Yu M; Zhao L; Zhu X; Bhasin S; Li Q; Ha E; Shi J; Farokhzad OC
Angew Chem Int Ed Engl; 2016 Jun; 55(25):7091-7094. PubMed ID: 27140428
[TBL] [Abstract][Full Text] [Related]
17. Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells.
Parmar MB; Arteaga Ballesteros BE; Fu T; K C RB; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
J Biomed Mater Res A; 2016 Dec; 104(12):3031-3044. PubMed ID: 27465922
[TBL] [Abstract][Full Text] [Related]
18. The Daniel K. Inouye College of Pharmacy Scripts: Targeted Nanocarrier Based Systems for the Treatment of Lung Cancer.
Youngren-Ortiz SR; Chougule MB
Hawaii J Med Public Health; 2017 Nov; 76(11):318-325. PubMed ID: 29164017
[TBL] [Abstract][Full Text] [Related]
19. A RNA nanotechnology platform for a simultaneous two-in-one siRNA delivery and its application in synergistic RNAi therapy.
Jang M; Han HD; Ahn HJ
Sci Rep; 2016 Aug; 6():32363. PubMed ID: 27562435
[TBL] [Abstract][Full Text] [Related]
20. Effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers.
Boyer C; Teo J; Phillips P; Erlich RB; Sagnella S; Sharbeen G; Dwarte T; Duong HT; Goldstein D; Davis TP; Kavallaris M; McCarroll J
Mol Pharm; 2013 Jun; 10(6):2435-44. PubMed ID: 23611705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
